A wealth of partnerships validate Philogen’s approach and science
Philogen offers collaborations based on its proprietary tumor-targeting platforms and will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to the development and commercialization of biologics.
The Philogen Group has signed collaboration and/or licensing agreements with large pharmaceutical companies including AbbVie, Bayer, Blue Earth Diagnostics (a subsidiary of Bracco), Boehringer Ingelheim, Celgene (a subsidiary of Bristol-Myers Squibb), IBSA, Janssen Biotech, Inc. (a Johnson & Johnson company), MedImmune (a wholly owned subsidiary of AstraZeneca), Merck-Serono, MSD, Novartis, Pfizer, Schering, Servier, Sun Pharmaceuticals and RayzeBio (a wholly owned subsidiary of BMS).
Our collaboration agreements with academic institutions include ETH Zurich, Scripps Research, The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), University of Zurich and Wyss Translational Center Zurich.
GMP manufacturing
In addition to its research facilities, Philogen has operated a GMP manufacturing plant in Montarioso near Siena, Italy, since 2004, authorized by the Italian Medicines Agency (AIFA) to manufacture investigational medicinal products. A second GMP plant in Rosia has been approved by AIFA for the commercial production of Philogen drugs. The nature and location of the Italian facilities enable GMP manufacturing and CRO drug-development activities to be conducted in an integrated manner.
Montarioso Facility
AIFA-authorized for investigational medicinal products, operating since 2004
Rosia Facility
AIFA-approved for commercial production of Philogen drugs
Philogen offers customized activities for cell line development and GMP manufacturing of biotherapeutics to selected industrial and academic partners in the frame of collaborations. Using Philogen´s GMP manufacturing plants in Montarioso and Rosia near Siena, Italy, we produce GMP-grade drug products to the highest regulatory standards that can be used for up to Phase III clinical trials.
R&D Discovery
Discovery runs through Philochem, the group’s Discovery Unit. Philochem offers flexible collaboration structures, adjusted to the requirements of the partner, for the screening of binders against few or several targets of choice.
- 01
DNA-encoded chemical libraries
Philochem has pioneered the development of the DNA-encoded library (DEL) technology, which opens new possibilities for drug discovery in a fast and cost-effective way. Philochem owns proprietary technologies and large DNA-encoded chemical libraries containing more than one billion compounds.
- 02
Antibodies and cyclic peptides
The Philogen Group has constructed and validated antibody phage libraries comprising more than 100 billion members. These proprietary libraries enable the fast and cost-effective isolation of fully human monoclonal antibodies against virtually any antigen of interest. The group also owns proprietary phage libraries of short cyclic peptides comprising more than 100 billion members.
For more information on the discovery platforms, please visit the Philochem website.
Clinical trials
Philogen runs and manages clinical trials in-house across all stages, from Phase I through Phase III.
Detailed clinical-trial service copy is being prepared and will be published here.
Bioanalytics
Alongside the GMP facility, we operate an Analytical Laboratory since 2016.
The Laboratory currently holds an ISO 9001:2015 and a GLP certificate as well as authorisation to operate analysis as Bioanalytical Laboratory (GCLP) allowing the analysis of samples deriving from pre-clinical and clinical studies.
The laboratory focuses on determining pharmacokinetics, immunogenicity and related biomarkers of immuno-cytokine drug products in non-clinical and clinical settings using various LBA technologies.
Moreover, Philogen offers GLP analysis services for biotherapeutics to selected industrial and academic partners in the frame of collaborations.
Partnering contacts
For collaboration opportunities, partnerships, or licensing agreements, please contact:
Biography
Frederik graduated in Pharmaceutical Sciences at ETH Zürich and performed an industrial Ph.D. at Philochem in which he focused on the generation and characterization of novel fully-human monoclonal antibodies. Frederik is author of several peer-reviewed publications in international scientific journals and joined the Business Development team at Philochem in 2023.
Biography
Laura Alvigini holds a Master’s degree in Chemistry from the University of Pavia (Italy), where she conducted her experimental thesis at CERN in Geneva, and a Ph.D. in Biochemistry and Structural Biology. During her PhD, she contributed to EU Horizon- and ERC Advanced Grant-funded research projects in Biocatalysis and Enzymology.
Laura joined Philochem in 2022 as a Senior Research Scientist, focusing on the development of a Peptide Phage Display platform for the discovery of novel peptide-based therapeutics.
In January 2026, she transitioned to the Operations and Business Development team, where she contributes to cross-functional activities in operational coordination, GMP manufacturing, and Business Development.